Related Experiment Videos
Antiplatelet and anticoagulant use after myocardial infarction
G T Almony1, J Lefkovits, E J Topol
1Department of Cardiology, Cleveland Clinic Foundation, OH 44195, USA.
Insights
Understanding coronary thrombosis and myocardial infarction has advanced antithrombotic therapies. This review covers current clinical data on antiplatelet, anticoagulant, and antithrombin treatments following heart attacks.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Pharmacology
Background:
- Coronary thrombosis, leading to myocardial infarction (MI), is a complex process involving arterial wall, coagulation cascade, and platelets.
- Advances in understanding thrombosis molecular biology have driven the evolution of antithrombotic therapy.
- Early treatments like warfarin have been succeeded by targeted agents modulating specific thrombotic pathways.
Purpose of the Study:
- To review current clinical data on antithrombotic therapies used after myocardial infarction.
- To highlight the evolution of antithrombotic strategies from broad anticoagulation to targeted interventions.
- To discuss the potential for combined therapies given the multiple pathways in thrombosis.
Main Methods:
- Literature review of clinical data on antithrombotic therapies.
- Analysis of antiplatelet, anticoagulant, and specific antithrombin agents.
- Focus on post-myocardial infarction treatment strategies.
Main Results:
- Current therapies include antiplatelet, anticoagulant, and specific antithrombin agents.
- Targeted agents offer specific modulation of thrombotic pathways.
- Combined therapies are feasible due to multiple intervention sites.
Conclusions:
- Significant progress has been made in antithrombotic therapy post-MI.
- Targeted and combination therapies represent the current standard of care.
- Continued research into thrombosis pathways informs therapeutic advancements.
Abstract:
Coronary thrombosis leading to myocardial infarction is a complex process involving the interaction of the arterial wall, the coagulation cascade, and platelets. Increased understanding of the molecular biology of thrombosis has prompted an evolution in antithrombotic therapy, from the early use of warfarin following myocardial infarction to agents targeting specific receptors or modulators in the thrombotic process. The complexity of thrombosis allows for numerous sites of pharmacologic intervention; the multiple pathways leading to platelet aggregation and thrombin formation provide the opportunity for combined therapies. This review presents the current clinical data on antiplatelet, anticoagulant, and specific antithrombin therapies following myocardial infarction.